Literature DB >> 24591096

Inhibition of cathepsin K increases modeling-based bone formation, and improves cortical dimension and strength in adult ovariectomized monkeys.

Brenda L Pennypacker1, Charles M Chen, Helen Zheng, Mei-Shu Shih, Mary Belfast, Rana Samadfam, Le T Duong.   

Abstract

Treatment with the cathepsin K (CatK) inhibitor odanacatib (ODN) protects against bone loss and maintains normal biomechanical properties in the spine and hip of ovariectomized (OVX) preclinical models. Here, we characterized the effects of ODN on the dynamics of cortical modeling and remodeling, and dimension and strength of the central femur in adult OVX-rhesus monkeys. Animals were treated with vehicle or ODN (6 or 30 mg/kg, once per day [q.d., p.o.]) in prevention mode for 21 months. Calcein and tetracycline double-labeling were given at 12 and 21 months, and the femoral cross-sections were subjected to dynamic histomorphometric and cement line analyses. ODN treatment significantly increased periosteal and endocortical bone formation (BFR/BS), accompanied with an increase in endocortical mineralizing surface (102%, p < 0.01) with the 6 mg/kg dose. ODN at both doses reduced remodeling hemiosteon numbers by 51% and 66% (p < 0.05), respectively, and ODN 30 mg/kg numerically reduced activation frequency without affecting wall thickness. On the same endocortical surface, ODN increased all modeling-based parameters, while reducing intracortical remodeling, consistent with the observed no treatment effects on cortical porosity. ODN 30 mg/kg markedly increased cortical thickness (CtTh, p < 0.001) and reduced marrow area (p < 0.01). Lastly, ODN treatment increased femoral structural strength (p < 0.001). Peak load was positively correlated with the increases in bone mineral content (BMC) (r(2)  = 0.9057, p < 0.0001) and CtTh (r2  = 0.6866, p < 0.0001). Taken together, by reducing cortical remodeling-based and stimulating modeling-based bone formation, ODN significantly improved cortical dimension and strength in OVX monkeys. This novel mechanism of CatK inhibition in stimulating cortical formation suggests that ODN represents a novel therapeutic approach for the treatment of osteoporosis.
© 2014 American Society for Bone and Mineral Research.

Entities:  

Keywords:  BONE FORMATION; CATHEPSIN K INHIBITOR; CORTICAL BONE; MODELING; NONHUMAN PRIMATE; OSTEOCLAST; OSTEOPOROSIS; OVARIECTOMY; REMODELING

Mesh:

Substances:

Year:  2014        PMID: 24591096     DOI: 10.1002/jbmr.2211

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  21 in total

Review 1.  Molecular and cellular basis of bone resorption.

Authors:  Reinhard Gruber
Journal:  Wien Med Wochenschr       Date:  2014-09-16

2.  Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study.

Authors:  R Rizzoli; C-L Benhamou; J Halse; P D Miller; I R Reid; J A Rodríguez Portales; C DaSilva; R Kroon; N Verbruggen; A T Leung; D Gurner
Journal:  Osteoporos Int       Date:  2016-02-15       Impact factor: 4.507

Review 3.  Contributions of Nonhuman Primates to Research on Aging.

Authors:  E S Didier; A G MacLean; M Mohan; P J Didier; A A Lackner; M J Kuroda
Journal:  Vet Pathol       Date:  2016-02-11       Impact factor: 2.221

Review 4.  Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned.

Authors:  Matthew T Drake; Bart L Clarke; Merry Jo Oursler; Sundeep Khosla
Journal:  Endocr Rev       Date:  2017-08-01       Impact factor: 19.871

Review 5.  Long-term safety of antiresorptive treatment: bone material, matrix and mineralization aspects.

Authors:  Barbara M Misof; Nadja Fratzl-Zelman; Eleftherios P Paschalis; Paul Roschger; Klaus Klaushofer
Journal:  Bonekey Rep       Date:  2015-02-11

Review 6.  Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis.

Authors:  Bente Langdahl; Serge Ferrari; David W Dempster
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-10-05       Impact factor: 5.346

Review 7.  Osteoclasts: more than 'bone eaters'.

Authors:  Julia F Charles; Antonios O Aliprantis
Journal:  Trends Mol Med       Date:  2014-07-06       Impact factor: 11.951

8.  The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club.

Authors:  E Cavalier; P Bergmann; O Bruyère; P Delanaye; A Durnez; J-P Devogelaer; S L Ferrari; E Gielen; S Goemaere; J-M Kaufman; A Nzeusseu Toukap; J-Y Reginster; A-F Rousseau; S Rozenberg; A J Scheen; J-J Body
Journal:  Osteoporos Int       Date:  2016-03-30       Impact factor: 4.507

Review 9.  Osteoporosis therapy: a novel insight from natural homeostatic system in the skeleton.

Authors:  T Sugiyama; Y T Kim; H Oda
Journal:  Osteoporos Int       Date:  2014-10-07       Impact factor: 4.507

10.  Activation, development, and attenuation of modeling- and remodeling-based bone formation in adult rats.

Authors:  Wenzheng Wang; Wei-Ju Tseng; Hongbo Zhao; Tala Azar; Shaopeng Pei; Xi Jiang; Nathaniel Dyment; X Sherry Liu
Journal:  Biomaterials       Date:  2021-07-09       Impact factor: 15.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.